More significantly, sorafenib non-responsive HCC patients demonstrated a notably higher expression of ISG15 in comparison to the responders (Fig. 5E), and this elevated ISG15 expression is indicative of an unfavorable prognosis among liver cancer patients (Fig. 5F). Here, ISG15 is linked to hepatocellular carcinoma.